The Effect of Early Treatment of PC945 on Aspergillus Fumigatus Lung Infection in Lung Transplant Patients.

Exclusion Criteria

• •Is precluded from participating in this study as a result of treatment with another investigational drug or participation in another clinical trial.
• •If female, the subject is pregnant, lactating or breast feeding.
• •Any other clinically significant disease or condition, which in the Investigator's medical opinion would preclude the subject's participation in a clinical trial (e.g., recent myocardial infarction).
• •Is employed or is a first-degree relative of anyone employed by Pulmocide, a participating clinical trial site, or any contract research organisation involved in the study.
• •Is receiving antiretroviral protease inhibitor therapy.
• •Has human immunodeficiency virus or chronic, active hepatitis infection, or had a positive hepatitis B surface antigen or hepatitis C virus RNA test prior to transplant.
• •Any known history or current evidence of alcohol or drug abuse that, in the Investigator's opinion, would exclude the subject from participation in the study
• •Clinical, endobronchial and/or radiological features of fungal disease.\*
• •Any other disease or condition, which in the Investigator's medical opinion would preclude the subject's participation in the Pre-Emptive Treatment Phase of the study (e.g., recent myocardial infarction).
• •Provided written informed consent for participating in the Follow-Up Phase for SoC antifungal treatment.
• •Any other disease or condition, which in the Investigator's medical opinion would preclude the subject's participation in the Follow-Up Phase for SoC antifungal treatment.